In this clinical leadership role, you will direct medical strategy and clinical development for our advanced cell-free DNA (cfDNA) and liquid biopsy portfolio, focusing on minimal residual disease (MRD) and recurrence monitoring for gynecologic malignancies (ovarian, endometrial, cervical, vulvar, and vaginal cancers). Partner with commercial and marketing teams to deliver clear, data-driven clinical evidence and educational materials to gynecologic oncology stakeholders, including gynecologic oncology surgeons, medical oncologists, pathologists, radiation oncologists, genetic counselors, and advanced practice providers.